Aa
Abstracts from APASLD2012
The abstracts are now available from the Hepatology International Journal, but access is restricted to registered members. Does anyone have membership?
http://www.springerlink.com/content/n70m780mw054/
http://www.springerlink.com/content/n70m780mw054/
http://www.lorenti.ch/apph/index.php?option=com_content&view=article&id=118&Itemid=132
link is from APPH 2011presetnation - but have some good information
link is from APPH 2011presetnation - but have some good information
Thanks. I did have a look. It certainly provides some of the abstracts that natap consider useful. Hopefully, they will have more soon.
http://www.natap.org/2012/APASL/APASL.htm
is this what you are looking for ? (don't had time to look over, but at first look looks like it is )
is this what you are looking for ? (don't had time to look over, but at first look looks like it is )
Only one I manage to get so far.
Here is the abstract about REP 9AC from APASLD 2012 Conference in Taiwan:
REP 9AC / REP 9AC’: Potent HBsAg release inhibitors that can rapidly elicit durable immunological control of infection in patients with chronic hepatitis B
Mamun-Al-Mahtab1, Michel Bazinet2 and Andrew Vaillant2
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2REPLICor Inc., Montreal, Canada
BACKGROUND: HBsAg suppresses host immunity and permits chronicity of HBV infection. REP9AC / REP9AC’ are nucleic acid-based polymers (NAPs) that block HBsAg release from infected hepatocytes. The current clinical results with REP9AC and a 4th generation NAP (REP9AC’) are disclosed.
METHODS: Patients with pre-treatment HBV DNA titers between 106 and 1012 copies/ml were treated by IV infusion. Virologic response was assessed using the Cobas and Architect testing platforms.
RESULTS (REP9AC): > 99.5% reduction of HBsAg occurred in seven of eight patients within 7 days to 32 weeks of treatment. All responders achieved 3 - 7 log reductions in HBV DNA. Four responders achieved complete control of their infection with 20-44 weeks of treatment (HBV DNA < 500cpm). Off treatment, three patients had sustained immunological control of their infection (HBV DNA < 500cpm, and HBsAg 90% reductions in HBsAg and 2-7 log reductions in HBV DNA). Mild pro-inflammatory side-effects accompanied drug administration.
RESULTS (REP9AC’): REP9AC’ is more stable with reduced pro-inflammatory activity compared to REP9AC. Interim data show robust HBsAg reductions in all seven patients in the first 10 weeks of treatment. Three patients have already experienced a 3-4 log decline in HBV DNA. Pro-inflammatory side-effects during administration were substantially reduced.
CONCLUSIONS: NAPs can affect rapid clearance of HBsAg, allowing restoration of host immunity. These results suggest that NAPs may become an important new tool in the treatment of chronic hepatitis B.
Here is the abstract about REP 9AC from APASLD 2012 Conference in Taiwan:
REP 9AC / REP 9AC’: Potent HBsAg release inhibitors that can rapidly elicit durable immunological control of infection in patients with chronic hepatitis B
Mamun-Al-Mahtab1, Michel Bazinet2 and Andrew Vaillant2
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2REPLICor Inc., Montreal, Canada
BACKGROUND: HBsAg suppresses host immunity and permits chronicity of HBV infection. REP9AC / REP9AC’ are nucleic acid-based polymers (NAPs) that block HBsAg release from infected hepatocytes. The current clinical results with REP9AC and a 4th generation NAP (REP9AC’) are disclosed.
METHODS: Patients with pre-treatment HBV DNA titers between 106 and 1012 copies/ml were treated by IV infusion. Virologic response was assessed using the Cobas and Architect testing platforms.
RESULTS (REP9AC): > 99.5% reduction of HBsAg occurred in seven of eight patients within 7 days to 32 weeks of treatment. All responders achieved 3 - 7 log reductions in HBV DNA. Four responders achieved complete control of their infection with 20-44 weeks of treatment (HBV DNA < 500cpm). Off treatment, three patients had sustained immunological control of their infection (HBV DNA < 500cpm, and HBsAg 90% reductions in HBsAg and 2-7 log reductions in HBV DNA). Mild pro-inflammatory side-effects accompanied drug administration.
RESULTS (REP9AC’): REP9AC’ is more stable with reduced pro-inflammatory activity compared to REP9AC. Interim data show robust HBsAg reductions in all seven patients in the first 10 weeks of treatment. Three patients have already experienced a 3-4 log decline in HBV DNA. Pro-inflammatory side-effects during administration were substantially reduced.
CONCLUSIONS: NAPs can affect rapid clearance of HBsAg, allowing restoration of host immunity. These results suggest that NAPs may become an important new tool in the treatment of chronic hepatitis B.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
